Flatiron Health today announced its presence at the American Society of Clinical Oncology (ASCO) Annual Meeting happening from May 29 – June 2, 2026, in Chicago, Illinois. Flatiron’s high-quality real-world data and innovative research capabilities are featured across 25+ research acceptances, including 14 Flatiron-authored poster presentations and online publications.
Flatiron’s presence at ASCO 2026 closely follows the launch of Flatiron Telescope, a multi-agent adaptive analytics platform designed to help life sciences teams find the right patients faster, assess study feasibility in real time, and generate oncology insights on demand. Flatiron Telescope will be demonstrated at the company’s booth (#21149) for attendees to build and iterate on patient cohorts using natural language and generate insights in real time.
“Our presence at ASCO 2026 proves that innovation and rigor aren’t at odds—they reinforce each other,” said Emily Castellanos, MD, MPH, Senior Medical Director and Head of Research Oncology at Flatiron Health. “From digital twins that simulate patient outcomes to LLM-enabled treatment pattern analysis, our work demonstrates that Flatiron is defining—not just participating in—the evolution of oncology evidence. These 25+ acceptances showcase our unified, global oncology engine and reinforce our position as the gold standard in oncology intelligence, trusted to guide the highest-stakes decisions across the industry.”
Research highlights include:
- Digital twin modeling for treatment prediction: validating novel counterfactual prediction approaches in NSCLC using clinical trial data, demonstrating how AI-enabled simulation can move beyond observational analysis to model patient outcomes under different treatment scenarios
- Physician adoption of landmark clinical trial findings: a large-language model-based analysis documenting how ASCO plenaries translate to clinical decision-making in real-world practice, the largest such analysis of clinician-patient trial discussions to date
- Recurrence risk prediction in early breast cancer: leveraging multi-site observational data to build predictive models for early breast cancer populations, showing how scale enables discovery in underrepresented patient groups
- Post-operative circulating tumor DNA as a prognostic indicator: examining ctDNA’s role in identifying high-recurrence risk in muscle-invasive and locally advanced bladder cancer, demonstrating the value of real-world biomarker data in routine practice
- Real-world treatment patterns in platinum-resistant ovarian cancer: analyzing platinum re-challenge outcomes in a population with limited evidence guidance, highlighting how Flatiron’s depth of longitudinal data reveals clinical practices that diverge from trial design and guidelines
Join Flatiron Health at booth #21149 for a demo of Flatiron Telescope and follow Flatiron Health on X and LinkedIn for more updates from #ASCO26.
Poster Presentations
From plenary to practice: a large language model (LLM)-based thematic analysis of landmark clinical trial discussions and factors influencing their real-world adoption
Aaron B Cohen, Tori Williams, Charu Aggarwal, Angela M DeMichele, Ritvik Vasudevan, Niquelle Brown Wadé, Shreya Balakrishna Rosseau, Erin Fidyk, Blythe Adamson
Author affiliations: Penn Medicine, Flatiron Health
Abstract Number: 1583
Poster Session: Care Delivery/Models of Care
Poster Board: 501
Date and Time: May 30, 2026, 9-12 PM
External validation of a deep learning CT biomarker to predict first-line immune checkpoint inhibitor monotherapy-associated survival in PD-L1-high metastatic non-small cell lung cancer
Ravi B. Parikh, Jacqueline Law, Lauren M. Damato, Paul M. Novotny, Joel Brooks, Ryan Beasley, Chiharu Sako, Petr Jordan, George R. Simon
Author affiliations: Emory University, Onc.AI, OhioHealth, Flatiron Health
Abstract Number: 2534
Poster Session: Developmental Therapeutics—Immunotherapy
Poster Board: 324
Date and Time: May 30, 2026, 1:30- 4:30 PM
Prognostic value of post-operative circulating tumor DNA (ctDNA) in real-world treatment and outcomes among patients (pts) with muscle invasive (MIBC) and locally advanced (LA) bladder cancer (BC)
Khilna Patel, Danni Zhao, Erin Fidyk, Eunice A. Hankinson, Aashay Mahesh Mehta, Matthew Pesavento, Arun Sujenthiran
Abstract Number: 4600
Poster Session: Genitourinary Cancer—Kidney and Bladder
Poster Board: 79
Date and Time: May 31, 2026, 9-12 PM
Real-world second-line treatment patterns and outcomes by platinum sensitivity in extensive-stage small cell lung cancer in the post-immunotherapy era
Catherine Rinaldi, Samantha Reiss, Jenna Collins, Karen Schwed, Michael Chiu, Emily Castellanos
Abstract Number: 8083
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 557
Date and Time: May 31, 2026, 9-12 PM
Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer
Apar Kishor Ganti, Jeremy Snider, Jessie T. Yan, Catherine Rinaldi, Amy Nguyen, Badri Rengarajan, Deb Profant, Douglas S. Fuller, Ellen Hu, Trong Kim Le, Navit Naveh, Xiaozhou Fan
Author affiliations: Jazz Pharmaceuticals, Nebraska Western Iowa Health Care System/University of Nebraska Medical Center, Flatiron Health
Abstract Number: 8093
Poster Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Poster Board: 567
Date and Time: May 31, 2026, 9-12 PM
A risk stratification schema for patients with non-small cell lung cancer with multiple organ metastases
Gabriela Esnaola, Mengru Wang, Benjamin Resio, Alexander Pan, Daniel Lee, Aaron B. Cohen, Maneet Kaur, Madeleine Schmitter, Jeffrey J. Ishizuka, Kelly Olino
Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number: 11138
Poster Session: Quality Care/Health Services Research Track
Poster Board: 121
Date and time: June 1, 2026, 9-12pm
Platinum re-challenge in platinum-resistant ovarian cancer: real-world patterns and outcomes
Prakirthi Yerram, Matt Bye, Khilna Patel, Nicole Nasrallah, Michael Curry, Emily Castellanos
Abstract Number: 5566
Poster Session: Gynecologic Cancer
Poster Board: 232
Date and Time: June 1, 2026, 9-12pm
Using ML to predict rapid progression for patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with frontline (1L) CDK 4/6 inhibitors (CDK 4/6i)
Michael Peng, Gabriel Rios, Melissa Estevez, Jamie Colasurdo, Mohammad Forouzanfar, Kelly Hoang, Meng Wang
Author affiliations: Gilead Sciences, IQVIA, Flatiron Health
Abstract Number: 1025
Poster Session: Breast Cancer—Metastatic
Poster Board: 139
Date and Time: June 1, 2026, 1:30-4:30 PM
RW post-progression outcomes following first-line (1L) ribociclib (RIB) + aromatase inhibitor (AI) versus AI alone in African American and low socio-economic status (SES) patients with HR+/HER2− metastatic breast cancer (MBC) in US.
Vk Gadi, Lowell L. Hart, Paolo Tarantino, Priyanka Sharma, Sarah L. Sammons, Panagiotis Mayros, Maneet Kaur, Nada Boualam, Catherine Keane, Gary M. Sopher, Purnima Pathak, Hope S. Rugo
Author affiliations: University of Illinois Cancer Center, Wake Forest University/Florida Cancer Specialists, Harvard Medical School, University of Kansas Medical Center, Dana-Farber Cancer Institute, Novartis, City of Hope Comprehensive Cancer Center, Flatiron Health
Abstract Number: 1073
Poster Session: Breast Cancer—Metastatic
Poster Board: 187
Date and Time: June 1, 2026, 1:30-4:30 PM
Recurrence risk prediction using a large, multi-site observational dataset of patients with early breast cancer including early-onset disease
Lilia Bouzit, Gabriel Rios, Smriti Karwa, Erin Fidyk, Catherine Keane, Melissa Estevez
Abstract Number: 547
Poster Session: Cancer—Local/Regional/Adjuvant
Poster Board: 32
Date and Time: June 1, 2026, 1:30-4:30 PM
Online Acceptances
Digital twin models for counterfactual prediction in NSCLC: a validation study using clinical trial data
Aaron B Cohen, Sandra Giffith, Melissa Estevez, Brandon Arnieri, Matt H Secrest, Joe Manfredonia, Marcello Ricottone, Richard Knoche, Jacqueline Law, Melina Marmarelis
Author affiliations: Genentech, University of Pennsylvania, Flatiron Health
Abstract Number for Publication: e20517
Real-world treatment patterns and outcomes among patients with high-risk and very high-risk non-metastatic prostate cancer
Eunice A. Hankinson,Yunzhi Qian, Patrick Ward, Khilna Patel, Aaron Dolor, Arun Sujenthiran
Abstract Number for Publication: e17120
Drivers of organotropism and patterns of metastatic progression in metastatic non-small cell lung cancer
Gabriela Esnaola, Benjamin Resio, Alexander Pan, Daniel Lee, Aaron B. Cohen, Mengru Wang, Madeleine Schmitter, Jeffrey J. Ishizuka, Kelly Olin
Author affiliations: Yale School of Medicine, Dana-Farber Cancer Institute, Flatiron Health
Abstract Number for Publication: e20541
Real-world biomarker testing rates, targeted therapy use, and clinical outcomes in patients with advanced gastric or GEJ cancer in the United States
Lauren Damato, Noelle S. Liao, Jonathan Bryan, Eunice A. Hankinson, Emily Castellanos
Abstract Number for Publication: e16039
About Flatiron
Flatiron Health transforms cancer care and research through a unified, global oncology engine powered by expert-validated AI and deep clinical and scientific expertise. Built from the experiences of millions of patients across the US, UK, Germany, and Japan, our real-world evidence informs the research, regulatory, commercial, and treatment decisions shaping oncology today. In the US, our point-of-care technology empowers clinicians to deliver smarter, more connected care while generating deeper insights that help advance cancer research. Flatiron Health is an independent affiliate of the Roche Group. Flatiron.com @FlatironHealth
View source version on businesswire.com: https://www.businesswire.com/news/home/20260521076927/en/
Media gallery
